Lexiva (Fosamprenavir, Telzir)
| Brand Name: |
Lexiva |
| Generic Name: |
Fosamprenavir calcium, FPV |
| Adult Single Dose: |
Therapy-naive patients: 1,400 mg twice daily; 1,400 mg once daily plus Norvir 200 mg once daily; 1,400 mg once daily plus Norvir 100 mg once daily; 700 mg twice daily plus Norvir 100 mg twice daily
Treatment-experienced patients: 700 mg twice daily plus Norvir 100 mg twice daily |
| Food & Liquid Restrictions: |
None |
| Drug Class: |
PI |
The Basics
- Fosamprenavir (Telzir, Lexiva) (December 14, 2012)
To read PDF, click here.
From AIDS InfoNet
- An Overview of Lexiva (Fosamprenavir, Telzir) (September 13, 2012)
From AIDSinfo
- Lexiva (March/April 2012)
To read PDF, click here.
In Positively Aware, from Test Positive Aware Network
- Patient Information About Lexiva (Fosamprenavir, Telzir) (PDF) (May 2011)
From ViiV Healthcare
- Lexiva (Fosamprenavir Calcium) -- Dear Health Care Professional Letter (December 3, 2009)
From U.S. Food and Drug Administration
- Labeling Update for Lexiva (Fosamprenavir) (December 21, 2007)
From U.S. Food and Drug Administration
- Lexiva (Fosamprenavir) (November 8, 2007)
Basic information on dosing schedules and side effects.
From U.S. Department of Veterans Affairs
- New Dosing Regimen for Lexiva Approved (October 12, 2007)
From U.S. Food and Drug Administration
- Fosamprenavir (908, Lexiva, Telzir) (August 15, 2006)
From AIDS Treatment Data Network
- Lexiva (Fosamprenavir) (May 2005)
To read PDF, click here.
From The Center for AIDS
VIEW ALL ARTICLES
News & Research
- Clinical Trials Using Fosamprenavir (Lexiva) (Regularly Updated)
U.S. and international trials currently recruiting.
From U.S. National Institutes of Health
- Fosamprenavir Pediatric Dosing Approved in U.S. for Ages 4 Weeks to <6 Years (May/June 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
- New Pediatric Lexiva Dosing Regimen for Patients From at Least 4 Weeks to Less Than 6 Years of Age (April 27, 2012)
From U.S. Food and Drug Administration
- Pharmacokinetics of Darunavir and Fosamprenavir in Pregnancy (July/August 2011)
To read PDF, click here.
- FDA: HIV Drug Lexiva Label to Warn of Cholesterol Increases (December 4, 2009)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- GlaxoSmithKline Announces New Program to Provide Financial Assistance for Eligible HIV Patients in the U.S. (November 11, 2008)
If you live in the United States, use private health insurance and take Combivir (AZT/3TC), Epzicom (abacavir/3TC, Kivexa), Lexiva (fosamprenavir, Telzir) or another HIV drug made by GlaxoSmithKline, you may have a chance to save a nice chunk of change.
From GlaxoSmithKline
- New Dosing Regimen for Lexiva Approved (October 12, 2007)
From U.S. Food and Drug Administration
- Agenerase (Amprenavir) Oral Solution and 50-mg Capsules to Be Discontinued in the U.S. (October 2007)
To read PDF, click here.
From GlaxoSmithKline
- FDA Approval of Lexiva Oral Suspension and Label Changes for Pediatric Patients and Patients With Hepatic Impairment (June 18, 2007)
From U.S. Food and Drug Administration
- Fosamprenavir Efficacy and Safety on Par With Other PIs, With No Gender-Based Differences (September 29, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy
VIEW ALL ARTICLES
|
|
Advertisement
|
Email
Glossary
